[1].Forner A, Reig M E, de Lope C R, et al. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis, 2010. 30(1): 61-74.
[2].Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC b stage hepatocellular carcinoma and treatment strategies: Proposal of modified bolondi's subclassification (Kinki criteria). Dig Dis, 2015. 33(6): 751-58.
[3].Golfieri R, Bargellini I, Spreafico C, et al. Patients with barcelona clinic liver cancer stages b and c hepatocellular carcinoma: Time for a subclassification. Liver Cancer, 2019. 8(2): 78-91.
[4].Wang Y Y, Zhong J H, Xu H F, et al. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther, 2019. 49(2): 202-10.
[5].Rhim H, Lim H K. Radiofrequency ablation of hepatocellular carcinoma: Pros and cons. Gut Liver, 2010. 4 Suppl 1: S113-18.
[6].Seo Y S, Kim M S, Yoo H J, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: A Markov model-based analysis. Cancer Med, 2016. 5(11): 3094-101.
[7].Hyun D, Cho S K, Shin S W, et al. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naive hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: Long-term outcomes. Acta Radiol, 2018. 59(7): 773-81.
[8].Marrero J A, Kulik L M, Sirlin C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology, 2018. 68(2): 723-50.
[9].Macia I G M. Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother, 2017. 22(2): 86-95.
[10].EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): 182-236.
[11].Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. Radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol, 2020. 73(1): 121-29.
[12].Moore A, Cohen-Naftaly M, Tobar A, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol, 2017. 12(1): 163.
[13].Eriguchi T, Tsukamoto N, Kuroiwa N, et al. Repeated stereotactic body radiotherapy for hepatocellular carcinoma. Pract Radiat Oncol, 2020(Online ahead of print).
[14].Loi M, Comito T, Franzese C, et al. Stereotactic body radiotherapy in hepatocellular carcinoma: Patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol, 2020(Online ahead of print).
[15].Baumann B C, Wei J, Plastaras J P, et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: High rates of local control with low toxicity. Am J Clin Oncol, 2018. 41(11): 1118-24.
[16].Wahl D R, Stenmark M H, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol, 2016. 34(5): 452-59.
[17].Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: A propensity score analysis. Hepatology, 2019. 69(6): 2533-45.
[18].Fu Y, Xi M, Pan Y, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: A retrospective cohort study. J Oncol, 2020. 2020: 4835653.
[19].Pollom E L, Lee K, Durkee B Y, et al. Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: A markov modeling study. Radiology, 2017. 283(2): 460-68.
[20].Pan Y X, Xi M, Fu Y Z, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: A retrospective propensity score matching study. Cancers (Basel), 2019. 11(8): 1116.
[21].Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of japan. Liver Cancer, 2014. 3(3-4): 458-68.
[22].Lencioni R, Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 2010. 30(1): 52-60.
[23].Wang F, Numata K, Nihonmatsu H, et al. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. Int J Hyperthermia, 2020. 37(1): 1149-58.
[24].Hao Y, Numata K, Ishii T, et al. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. World J Gastroenterol, 2017. 23(17): 3111-21.
[25].Takeda A, Sanuki N, Tsurugai Y, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer, 2016. 122(13): 2041-49.
[26].Zeng Z C, Seong J, Yoon S M, et al. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer, 2017. 6(4): 264-74.
[27].Llovet J M, Lencioni R. MRECIST for HCC: Performance and novel refinements. J Hepatol, 2020. 72(2): 288-306.
[28].Kunzli B M, Abitabile P, Maurer C A. Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. World J Hepatol, 2011. 3(1): 8-14.
[29].Yoon J H, Lee J M, Klotz E, et al. Prediction of local tumor progression after radiofrequency ablation (RFA) of hepatocellular carcinoma by assessment of ablative margin using Pre-RFA MRI and Post-RFA CT registration. Korean J Radiol, 2018. 19(6): 1053-65.
[30].Yip C, Hennedige T P, Cook G J, et al. Imaging assessment after SBRT for hepatocellular carcinoma. Hepatoma Research, 2020. 6(44): 1-08.
[31].Rim C H. Response to Letter to the Editor by Johnston and Fotiadis regarding "Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review.". Radiother Oncol, 2020.
[32].Tetreau R, Llacer C, Riou O, et al. Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother, 2017. 22(2): 170-75.
[33].Mendiratta-Lala M, Masch W, Shankar P R, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: Long term imaging Follow-Up. Int J Radiat Oncol Biol Phys, 2019. 103(1): 169-79.
[34].Zhao Z, Wu J, Liu X, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett, 2018. 421: 73-81.
[35].Zhang N, Li H, Qin C, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol, 2019. 145(4): 895-907.
[36].Kang T W, Lim H K, Cha D I. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol, 2017. 23(1): 95-101.
[37].Kang T W, Kim J M, Rhim H, et al. Small hepatocellular carcinoma: Radiofrequency ablation versus nonanatomic Resection--Propensity score analyses of long-term outcomes. Radiology, 2015. 275(3): 908-19.
[38].Brillet P Y, Paradis V, Brancatelli G, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: A prospective study with histopathologic comparison. AJR Am J Roentgenol, 2006. 186(5 Suppl): S296-305.
[39].Cassinotto C, Aube C, Dohan A. Diagnosis of hepatocellular carcinoma: An update on international guidelines. Diagn Interv Imaging, 2017. 98(5): 379-91.